Basic Overview of Tuberculosis Epidemiology in the Czech Republic in 2017

Similar documents
Basic Overview of Tuberculosis Epidemiology in the Czech Republic in 2015

HPV vaccination in the Czech Republic

Can epidemiological data contribute to improvement in cancer care?

Evaluation of communication strategy and publicity of RDI OP

COLORECTAL CANCER: A CHALLENGE FOR HEALTHY LIFESTYLE, SCREENING AND PROPER CARE

Epidemiology of tuberculosis in Europe. Marieke J. van der Werf European Centre for Disease Prevention and Control Amsterdam, 22 September 2014

2016 Annual Tuberculosis Report For Fresno County

TUBERCULOSIS CONTROL IN THE WHO WESTERN PACIFIC REGION In the WHO Western Pacific Region 2002 Report

Factors Associated with Multidrugresistant Tuberculosis: Comparison of Patients Born Inside and Outside of the Czech Republic

Assessing the programmatic management of drug-resistant TB

Epidemiology of tuberculosis in Northern Ireland. Annual surveillance report 2007

Annual surveillance report 2015

NATIONAL TUBERCULOSIS CONTROL PROGRAMME- SCC AREA Quarterly Report on New and Retreatment Cases of Tuberculosis

Clinical CRC registries of the Czech Society for Oncology

Health Protection Surveillance Centre

Drug Situation in the Czech Republic in Annual Report Summary. Zaostřeno na drogy Special edition

ANNEXURE A: EXPLANATORY NOTES ON THE DMR 164 REPORTING ON HIV AND TB FORM

South West. Tuberculosis Treatment Outcome Surveillance for the South West

Osaka City is the third largest city (population

GUIDELINES, STATEMENTS & STANDARDS ON TUBERCULOSIS [AS OF NOVEMBER 2004] PART I. GROUPED BY AGENCY/ORGANIZATION

Revised National Tuberculosis Control Programme

GUIDELINES, STATEMENTS & STANDARDS ON TUBERCULOSIS [AS OF FEBRUARY 2005] PART I. GROUPED BY AGENCY/ORGANIZATION

Summary Statistics of Reported and Verified Cases of Tuberculosis in San Joaquin County in 2012, (N=44) County Rate = 6.3 Cases per 100,000 Population

Research Article Photovoice: A Novel Approach to Improving Antituberculosis Treatment Adherence in Pune, India

Appendix B. Recommendations for Counting Reported Tuberculosis Cases (Revised July 1997)

Annual surveillance report 2016

NEW YORK STATE DEPARTMENT OF HEALTH CLINICAL LABORATORY EVALUATION PROGRAM

Tuberculosis in Chicago 2007

Tuberculosis in Wales Annual Report 2015

The status of care for persons with von Willebrand disease registered within CNHP registry Annual Report 2017

Globally, it is well documented that certain

Supplementary Appendix

Annual Epidemiological Report

Lessons learnt from cancer screening programmes as an example for establishing the Czech National Coordination Centre

Appendix C. Recommendations for Counting Reported Tuberculosis Cases (Revised July 1997)

Overview of radiation oncology in the Czech Republic

Study of Multi-Drug Resistance Associated with Anti-Tuberculosis Treatment by DOT Implementation Strategy in Pakistan

Tuberculosis in Chicago 2006

Tuberculosis in Wales Annual Report 2013

Authors Malhotra, S; Zodpey, S P; Chandra, S; Vashist, R P; Satyanaryana, S; Zachariah, R; Harries, A D

RISK FACTORS FOR POOR TUBERCULOSIS TREATMENT OUTCOMES IN MAKASSAR, INDONESIA

4/25/2012. The information on patterns of infection and disease can assist in: Assessing current and evolving trends in TB

Tuberculosis surveillance in Germany. Data of the tuberculosis report 2013

The Epidemiology of Tuberculosis in Minnesota,

NEW YORK STATE DEPARTMENT OF HEALTH CLINICAL LABORATORY EVALUATION PROGRAM

National Disease Surveillance Centre

Revised National Tuberculosis Control Programme (RNTCP) Dr.Kishore Yadav J Assistant Professor

Role of RNTCP in the management MDR-TB

Tuberculosis in Wales Annual Report 2014

Tuberculosis in NSW,

UNIVERSITY OF MEDICINE AND PHARMACY CRAIOVA DOCTORAL THESIS ABSTRACT

Tuberculosis in South West Centre: Annual review (2014 data) Data from 2000 to 2014

Global epidemiology of drug-resistant tuberculosis. Factors contributing to the epidemic of MDR/XDR-TB. CHIANG Chen-Yuan MD, MPH, DrPhilos

2013 Annual Report Tuberculosis in Fresno County. Department of Public Health

Intensified TB case finding among PLHIV and vulnerable population Identifying contacts Gunta Kirvelaite

Yakima Health District BULLETIN

Tuberculosis Impact in Boston Residents: 2012

Tuberculosis Epidemiology

Multidrug- and extensively drug-resistant tuberculosis: a persistent problem in the European Union European Union and European Economic Area

Keywords: Tuberculosis; Pulmonary and Extra-Pulmonary Forms; Therapeutic Evaluation; Rural Area; West Algeria

Title: Meta-analysis of Individual patient Data (IPD) of Patients with INH (mono or poly-drug) Resistant Tuberculosis.

Appendix B. Recommendations for Counting Reported Tuberculosis Cases (Revised July 1997)

Tuberculosis Impact in Boston Residents: 2014

Scott Lindquist MD MPH Tuberculosis Medical Consultant Washington State DOH and Kitsap County Health Officer

TB IN EMERGENCIES. Disease Control in Humanitarian Emergencies (DCE)

Tuberculosis in the UK. Annual report on tuberculosis surveillance in the UK 2008

xxxxx Geographical size: km² Population: (2014) EU member country since: 1 May 2004

ANNUAL TUBERCULOSIS REPORT OREGON Oregon Health Authority Public Health Division TB Program November 2012

Predicting outcomes and drug resistance with standardised treatment of active tuberculosis

TUBERCULOSIS IN JAPAN

Application for addition of 3-FDC rifampicin 150/isoniazid 75/ethambutol 275 mg (RHE) to the WHO model list of essential medicines

Frances Morgan, PhD October 21, Comprehensive Care of Patients with Tuberculosis and Their Contacts October 19 22, 2015 Wichita, KS

THE CZECH REPUBLIC New Development, Trends and in-depth information on selected issues

Global, National, Regional

MDR, XDR and Untreatable Tuberculosis and Laboratory Perspectives. Martie van der Walt TUBERCULOSIS EPIDEMIOLOGY & INTERVENTION RESEARCH UNIT

REVIEW OF TUBERCULOSIS EPIDEMIOLOGY

T uberculosis control aims to reduce mortality and morbidity

Kulakhmet Dildakhmetovich Yerimbetov, Askar Shintasovich Zetov, Tleukhan Abildayev, Gulbadan Sabitovna Bekembayeva, Shahimurat Shaimovych Ismailov

Global, National, Regional

Guidelines for TB contact tracing in Pacific Island countries and territories

TB Control in Finland - the role of THL

Drug-resistant Tuberculosis

Ibrahim Abubakar, MBBS, MSc, PhD, FFPH

Tuberculosis in Wales Annual Report 2016

A Profile of Adverse Effects of Anti-Tubercular Drugs

11/3/2009 SECOND EDITION Madhukar Pai McGill University. ISTC Training Modules Introduction

Annual Tuberculosis Report Oregon 2007

Diagnosis of drug resistant TB

Information Note. WHO call for patient data on the treatment of multidrug- and rifampicin resistant tuberculosis

Treatment of Active Tuberculosis

Tuberculosis Now! Jon S Friedland MA, FRCPE, FMedSci. Infectious Diseases & Immunity

DRUG RESISTANCE IN TUBERCULOSIS

New Tuberculosis Guidelines. Jason Stout, MD, MHS

Drug susceptibility testing for tuberculosis KRISTEN DICKS, MD, MPH DUKE UNIVERSITY MEDICAL CENTER

2014 Annual Report Tuberculosis in Fresno County. Department of Public Health

Introduction. Diagnosis of extrapulmonaryand paediatric tuberculosis. Extrapulmonary tuberculosis EPTB SASCM WORKSHOP 2014/05/24

I. Demographic Information GENDER NUMBER OF CASES PERCENT OF CASES. Male % Female %

TUBERCULOSIS. Presented By: Public Health Madison & Dane County

What Is TB? 388 How TB Is Spread 388 How to Know if a Person Has TB 389 How to Treat TB 389 Resistance to TB medicines 390

Amit R. Dedun*, Ghanshyam B. Borisagar, Rajesh N. Solanki

Transcription:

Centre for the development of technology platform used in registries of the National Health Information System, modernisation of data mining within these registries and extending their information capacity. Development of the NHIS Technology Platform CZ.03.4.74/0.0/0.0/15_019/0002748 Development of the NHIS Technology Platform Basic Overview of Tuberculosis Epidemiology in the Czech Republic in 2017 Czech Health Statistics Published by the Institute of Health Information and Statistics of the Czech Republic Palackého nám. 4, Prague, Czech Republic www.uzis.cz European Union European Social Fund Operational Programme Employment Institute of Health Information and Statistics of the Czech Republic Institute of Biostatistics and Analyses of the Masaryk University Joint workplace Development of the NHIS Technology Platform

Contents Introduction... 3 Methodology... 3 Summary of Results... 4 Table 1. Reported of TB cases in regions of the Czech Republic... 6 Table 2. Reported of TB cases by age groups and sex... 7 Table 3. Reported of TB cases by previous treatment in regions of the Czech Republic... 8 Table 4. Reported of TB cases by disease location in regions of the Czech Republic... 9 Table 5. Resistance to antitubercular drugs... 10 Table 6. Reported of TB cases in foreign nationals by country of birth.. 12 Table 7. Evaluation of antituberculosis therapy at 12 months after its start in TB cases reported into RTB in 2016 (Treatment outcome monitoring)... 13 Table 8. Reported of TB deaths in regions of the Czech Republic... 14 Table 9. Reported of cases of mycobacterial infections other than TB.. 15 Table 10. Reported of cases of mycobacterial infections other than TB in regions of the Czech Republic... 16 www.uzis.cz ÚZIS ČR, 2018 2

Basic Overview of Tuberculosis Epidemiology in the Czech Republic in 2017 Introduction The publication Basic Overview of Tuberculosis Epidemiology in the Czech Republic in 2017 picks up the threads of the publication Tuberculosis and Respiratory Diseases, which was regularly published by the Institute of Health Information and Statistics of the Czech Republic (IHIS) from 1960 to 2014. It is a selection of the most important review tables describing the occurrence of reported cases of tuberculosis (TB) and other mycobacterial infections in the Czech Republic. The presented data were obtained from the Register of Tuberculosis (RTB), which is part of an information system maintained by public health protection authorities, and which is run as a web application based on a central database. Furthermore, the Information System of Bacillary Tuberculosis (ISBT) has become an inseparable part of RTB. In the Czech Republic, all detected cases of tuberculosis or other mycobacterial infections must be reported into RTB. Apart from RTB data, data from the Czech Statistical Office are used to calculate rates per population. RTB is administered by the Ministry of Health of the Czech Republic (MZ CR), namely by its Department of Strategy and Management of Public Health Protection and Promotion. Data on the national level are processed by IHIS, which is also responsible for providing and publishing statistical outputs and, together with the National Tuberculosis Surveillance Unit, maintains contacts with international organisations. The binding regulations in this domain involve: Act No. 258/2000 Coll. on Protection of Public Health and Amendment to Some Related Acts; Decree No. 306/2012 Coll. of MZ CR on Conditions of Prevention and Spread of Infectious Diseases and Hygiene Requirements for the Operation of Medical Facilities and Social Care Institutions; Decree No. 473/2008 Coll. of MZ CR on System of Epidemiological Vigilance for Selected Infections, as subsequently amended; and Standard of Follow-Up Care for Patients with Tuberculosis and Other Mycobacterial Infections and for Persons at a Higher Risk of These Diseases (Bulletin No. 7/2016 of MZ CR). In the context of evaluation of TB epidemiology in the Czech Republic, a new online and publicly available data-mining tool will be developed during the year 2018, providing a better insight into this issue; the tool will be designed in an interactive way, offering many different (and adjustable) points of view. Methodology The tabular outputs summarise TB epidemiology in the Czech Republic in 2017, based on data from RTB valid as of 20 June 2018. The reported cases of disease are assessed from many points of view, such as laboratory verification of the disease, age groups and sex, previous treatment, disease location, sensitivity to antitubercular agents, patient s death or country of birth. Information on the evaluation of antituberculosis therapy at 12 months after its start is linked to cases reported into RTB in 2016. The last two tables, unlike all the preceding ones, provide information on reported cases of mycobacterial infections other than TB. Data are available both as absolute and as standardised indicators. 3

Summary of Results In 2017, a total of 505 TB cases (i.e. 4,8 cases per 100 000 population), involving all forms and locations, were reported into RTB (Table 1). Compared with the previous year, the number of reported cases has decreased slightly (in 2017, there were 12 less than in 2016). There has been a continuous downward trend in TB incidence in the Czech Republic in the long term, and the burden has been low when compared to other countries. Among the reported patients, there were 33 persons who had been previously treated with antitubercular agents (Table 3). From the total number of reported TB cases in 2017, definitive diagnosis of TB was confirmed in 372 cases 73,7% (in the Hradec Králové Region, only 12 out of 27 reported TB cases (44,4%) were positive culturally), of which 307 cases were verified from sputum or from the laryngeal swab (LS). Sputum smear microscopy was positive in 184 patients (36,4%) (Table 1). According to RTB data, pulmonary TB was reported in 439 cases (86,9%); these cases also involved patients who had both pulmonary and extrapulmonary TB. By contrast, extrapulmonary TB only was reported in 66 cases (Table 4). TB occurred much more frequently in men than in women: men accounted for over than 70% of cases. The highest of patients were in older age categories. TB was most frequently reported in people aged 40 59 years; when recalculated per 100 000 population, people aged over 80 years were most frequently affected. When compared to 2016, the number of patients in younger age groups was lower; there was a year-on-year decrease in TB cases reported among patients younger than 20 years: 13 (in 2017, there were 5 less cases than in 2016) and in the age group of 25 29 years: 34 (6 less cases). Among patients there were 6 in the age group of 0 14 years (in 2017, there were 4 less cases than in 2016), of which 5 were under 5 years of age and 1 aged 10 14 years (Tab. 2). Just as in previous years, the Capital of Prague was the residence of most TB patients (95; 7,4 per 100 000 population) reported in 2017. Higher of TB cases than the national mean of 4,8 per 100 000 population were also reported in the Plzeň Region (7,6 per 100 000), the Ústí nad Labem Region (6,7 per 100 000), the Pardubice region (5,6 per 100 000), the South Moravian Region (5,6 per 100 000), the Liberec Region (5,0 per 100 000) and the Hradec Králové region (4,9 per 100 000). By contrast, the lowest absolute of TB cases were reported in the Karlovy Vary Region (8; 2,7 per 100 000) and the lowest relative in South Bohemian Region (16; 2,5 per 100 000) (Table 1). TB cases in 159 foreign nationals (i.e. persons born outside the Czech Republic) were reported into RTB in 2017, accounting more than 31,5% of the total number of reported TB cases. Most of these people were citizens of Ukraine (30 persons), Slovakia (25), Vietnam (23), Mongolia (16) and Romania (16) (Table 6). In 2017, sensitivity to antitubercular agents was tested in 350 patients. Isoniazid, streptomycin, pyrazinamid, rifampicin and ethambutol resistance were detected in 16 (4,6%), 15 (4,3%), 14 (4,0%), 8 (2,3%) and 7 (2,0%) cases, respectively. Multidrug-resistant TB was detected in 8 cases (2,3%). More information on resistance to antitubercular drugs is available in Table 5. From the total number of newly detected TB cases in 2016 that were verified from sputum or from the laryngeal swab (299 cases), evaluation of antituberculosis therapy at 12 months after its start (Treatment outcome monitoring) has shown that 206 persons (68,9%) were successfully treated and 39 persons (13,0%) died, out of which 12 died from TB. After one year, treatment continued 4

in 8 persons (2,7%). Nine persons (3,0%) moved elsewhere; treatment was interrupted or data on treatment were missing in 37 persons (12,4%) (Table 7). In 2017, a total of 36 TB deaths were reported into RTB (this number may include additionally reported deaths from previous periods); the highest of deaths were reported in the Capital of Prague (8 persons) (Table 8). Apart from tuberculosis, cases of other mycobacterial infections are reported into RTB, too. In 2016, there were 89 reported cases of other mycobacterial infections (in 2016, there were 106 cases), i.e. 0,84 cases per 100 000 population. Within these cases, there were 71 cases with pulmonary location and 18 cases with extrapulmonary location. M. avium (47 cases) and M. kansasii (12 cases) were the most frequently isolated strains (Table 9). Mycobacterial infections are most frequently reported in the Moravian-Silesian Region (17 cases) and the Olomouc Region (11 cases) (Table 10). 5

Table 1. Reported of TB cases in regions of the Czech Republic Territory, region 1) Reported TB cases in total absolute per 100,000 population Czech Republic 505 4.77 372 3.51 307 2.90 184 1.74 Capital of Prague 95 7.38 82 6.37 67 5.21 41 3.19 Central Bohemian 49 3.64 39 2.90 33 2.45 17 1.26 South Bohemian 16 2.50 14 2.19 10 1.56 8 1.25 Plzeň 44 7.60 33 5.70 29 5.01 13 2.24 Karlovy Vary 8 2.70 7 2.36 6 2.03 5 1.69 Ústí nad Labem 55 6.70 40 4.87 35 4.26 20 2.44 Liberec 22 4.99 14 3.18 14 3.18 12 2.72 Hradec Králové 27 4.90 12 2.18 10 1.82 3 0.54 Pardubice 29 5.61 20 3.87 17 3.29 7 1.35 Vysočina 13 2.56 9 1.77 5 0.98 4 0.79 South Moravian 66 5.59 47 3.98 35 2.96 18 1.52 Olomouc 21 3.32 15 2.37 14 2.21 11 1.74 Zlín 15 2.57 12 2.06 9 1.54 3 0.51 Moravian-Silesian 45 3.73 28 2.32 23 1.90 22 1.82 1) Regions of patients residence are reported Culturally positive TB cases absolute per 100,000 population Culturally positive TB cases, verification from sputum or LS absolute per 100,000 population Sputum smear microscopy positive TB cases absolute per 100,000 population 6

Table 2. Reported of TB cases by age groups and sex Age group (years) absolute Reported TB cases per 100,000 population total men women total men women 0 4 5 4 1 0.90 1.40 0.37 5 9 - - - - - - 10 14 1 1-0.20 0.38-15 19 7 1 6 1.52 0.42 2.68 20 24 22 13 9 4.08 4.71 3.42 25 29 34 23 11 4.99 6.60 3.30 30 34 38 27 11 5.23 7.21 3.12 35 39 41 31 10 4.92 7.23 2.48 40 44 47 37 10 5.09 7.79 2.23 45 49 45 33 12 6.19 8.86 3.39 50 54 59 47 12 8.46 13.28 3.50 55 59 55 44 11 8.81 14.14 3.51 60 64 39 32 7 5.53 9.43 1.92 65 69 40 33 7 5.82 10.37 1.89 70 74 20 12 8 3.63 4.99 2.58 75 79 21 13 8 6.01 9.18 3.86 80 84 21 11 10 9.21 13.28 6.89 85 89 6 1 5 4.28 2.25 5.22 90 94 4 2 2 8.09 15.81 5.44 Total 505 365 140 4.77 7.01 2.60 7

Table 3. Reported of TB cases by previous treatment in regions of the Czech Republic Territory, region 1) yes no yes no Czech Republic 33 472 0.31 4.46 Capital of Prague 7 88 0.54 6.84 Central Bohemian - 49-3.64 South Bohemian 2 14 0.31 2.19 Plzeň 4 40 0.69 6.91 Karlovy Vary - 8-2.70 Ústí nad Labem 5 50 0.61 6.09 Liberec 2 20 0.45 4.53 Hradec Králové 4 23 0.73 4.18 Pardubice 3 26 0.58 5.03 Vysočina - 13-2.56 South Moravian 4 62 0.34 5.25 Olomouc - 21-3.32 Zlín 2 13 0.34 2.23 Moravian-Silesian - 45-3.73 1) Regions of patients residence are reported absolute previously treated Reported TB cases per 100,000 population previously treated 8

Table 4. Reported of TB cases by disease location in regions of the Czech Republic Territory, region 1) Pulmonary TB (pulmonary TB only and both pulmonary and extrapulmonary TB) absolute Extrapulmonary TB (only) Czech Republic 439 4.15 66 0.62 Capital of Prague 84 6.53 11 0.85 Central Bohemian 44 3.27 5 0.37 South Bohemian 13 2.03 3 0.47 Plzeň 42 7.25 2 0.35 Karlovy Vary 8 2.70 0 0.00 Ústí nad Labem 48 5.85 7 0.85 Liberec 19 4.31 3 0.68 Hradec Králové 20 3.63 7 1.27 Pardubice 26 5.03 3 0.58 Vysočina 10 1.97 3 0.59 South Moravian 55 4.66 11 0.93 Olomouc 17 2.69 4 0.63 Zlín 14 2.40 1 0.17 Moravian-Silesian 39 3.23 6 0.50 1) Regions of patients residence are reported per 100,000 population absolute per 100,000 population 9

Table 5. Resistance to antitubercular drugs Reported TB cases Resistance previously treated yes previously treated no total abs. % abs. % abs. % Patients with TB resistant to certain drugs 18 100.0 332 100.0 350 100.0 Any resistance to: isoniazid (H) 4 22.2 12 3.6 16 4.6 rifampicin (R) 4 22.2 4 1.2 8 2.3 ethambutol (E) 2 11.1 5 1.5 7 2.0 streptomycin (S) 4 22.2 11 3.3 15 4.3 pyrazinamid (Z) 3 16.7 11 3.3 14 4.0 Resistance only to: isoniazid (H) - - 3 0.9 3 0.9 rifampicin (R) - - - - - - ethambutol (E) - - 1 0.3 1 0.3 streptomycin (S) - - 3 0.9 3 0.9 pyrazinamid (Z) 1 5.6 9 2.7 10 2.9 Mono-resistance in total 1 5.6 16 4.8 17 4.9 H + R - - - - - - H + R + E - - - - - - H + R + S 1 5.6 - - 1 0.3 H + R + Z - - - - - - H + R + E + S 1 5.6 2 0.6 3 0.9 H + R + E + Z - - 1 0.3 1 0.3 H + R + S + Z 1 5.6 - - 1 0.3 H + R + E + S + Z 1 5.6 1 0.3 2 0.6 Multidrug resistance (MDR) in total 4 22.2 4 1.2 8 2.3 H + E - - - - - - H + S - - 5 1.5 5 1.4 H + Z - - - - - - H + E + S - - - - - - H + E + Z - - - - - - H + S + Z - - - - - - H + E + S + Z - - - - - - R + E - - - - - - 10

Table 5. Resistance to antitubercular drugs Reported TB cases Resistance previously treated yes previously treated no total abs. % abs. % abs. % R + S - - - - - - R + Z - - - - - - R + E + S - - - - - - R + E + Z - - - - - - R + S + Z - - - - - - R + E + S + Z - - - - - - E + S - - - - - - E + Z - - - - - - E + S + Z - - - - - - S + Z - - - - - - Poly-resistance in total (other than MDR) - - 5 1.5 5 1.4 11

TBC 2017 Table 6. Reported of TB cases in foreign nationals by country of birth Reported TB cases % of the total number Year out of which total of reported Ukraine Slovakia Vietnam Mongolia Romania other TB cases 2017 159 30 25 23 16 16 49 31.5 12

Table 7. Evaluation of antituberculosis therapy at 12 months after its start in TB cases reported into RTB in 2016 (Treatment outcome monitoring) Treatment outcome Total number of reported TB cases in 2016 TB was excluded Verified TB cases reported in 2016 Cured / treatment completed Death from TB from another cause Treatment interrupted / missing data / missing follow-up report Still on treatment Patient transferred Treatment failed Reported TB cases in total Newly diagnosed TB cases, verification from sputum or LS abs. % abs. % 517 x 299 x 1.0 x - x 516 100.0 299 100.0 348 67.4 206 68.9 29 5.6 12 4.0 57 11.0 27 9.0 56 10.9 37 12.4 10 1.9 8 2.7 15 2.9 9 3.0 1 0.2 - - 13

Table 8. Reported of TB deaths in regions of the Czech Republic 2) Territory, region 1) Number of deaths absolute per 100,000 population Czech Republic 25 0.24 Capital of Prague 6 0.47 Central Bohemian 2 0.15 South Bohemian 1 0.16 Plzeň 3 0.52 Karlovy Vary 2 0.68 Ústí nad Labem 3 0.37 Liberec - - Hradec Králové 2 0.36 Pardubice 2 0.39 Vysočina 1 0.20 South Moravian 1 0.08 Olomouc - - Zlín 1 0.17 Moravian-Silesian 1 0.08 1) Regions of patients residence are reported 2) Including additionally reported deaths from previous periods 14

Table 9. Reported of cases of mycobacterial infections other than TB Disease group Patients with mycobacterial infections Diagnosis A31 absolute per 100,000 population Pulmonary mycobacterial infection 71 0.67 Extrapulmonary mycobacterial infection 18 0.17 Reported infections in total 86 0.81 out of which, the following strains were isolated: M. avium 47 0.44 M. intracelullare 9 0.08 M. kansasii 12 0.11 M. xenopi 8 0.08 other M. 10 0.09 15

Table 10. Reported of cases of mycobacterial infections other than TB in regions of the Czech Republic Territory, region 1) Czech Republic 71 0.67 18 0.17 Capital of Prague 6 0.47 1 0.08 Central Bohemian 5 0.37 1 0.07 South Bohemian 5 0.78 1 0.16 Plzeň 7 1.21 1 0.17 Karlovy Vary 1 0.34 - - Ústí nad Labem 4 0.49 1 0.12 Liberec 2 0.45 - - Hradec Králové 4 0.73 2 0.36 Pardubice 2 0.39 - - Vysočina 3 0.59 1 0.20 South Moravian 2 0.17 6 0.51 Olomouc 11 1.74 2 0.32 Zlín 2 0.34 1 0.17 Moravian-Silesian 17 1.41 1 0.08 1) Regions of patients residence are reported Reported cases of pulmonary mycobacterial infections absolute per 100,000 population Reported cases of extrapulmonary mycobacterial infections absolute per 100,000 population 16